Compare Palantir Technologies Inc (PLTR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Smith & Nephew plc — how do they compare? Palantir Technologies Inc trades at $168.85 (market cap $409.24B), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Palantir Technologies Inc is far larger — about 35.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.85% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| PLTR | SNN | |
|---|---|---|
Market Cap | $409.24B | $11.63B |
Sector | Technology | Health |
52-Week High | $207.18 | $38.53 |
52-Week Low | $107.27 | $27.80 |
Enterprise Value | $400.04B | $14.66B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir Technologies (PLTR) trades at $170.30, down 2.31% on the day but remains in a strong uptrend with recent earnings beats driving momentum. The stock shows robust fundamentals with 93% revenue growth in Q2 2026 and a 49% net income margin, though valuation metrics remain elevated with a P/E of 145.6. Technical indicators are neutral with support at $168 and resistance at $174, while the recent Nebius partnership strengthens Palantir's sovereign AI positioning.
Palantir's outlook remains positive with strong earnings momentum and strategic AI partnerships, though premium valuation and competitive pressures present risks. The consensus price target of $211.38 suggests 24% upside potential, supported by 50% analyst buy ratings. Key risks include valuation sustainability and compute capacity constraints as demand surges.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
